Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Suzanne Maahs"'
Autor:
Denise Leclair, Katherine M. Waye, Baltazar Gomez-Mancilla, Brian D. Kiluk, Ananda Krishna Karanam, Partha S. Banerjee, Velusamy Shanmuganathan Muthusamy, Suzanne Maahs
Publikováno v:
Frontiers in Psychiatry, Vol 15 (2024)
BackgroundThere is a paucity of literature describing experiences and journey of individuals with cocaine use disorder (CUD) and supporters who care for them. The aim of this study was to understand and document the journey of individuals with curren
Externí odkaz:
https://doaj.org/article/9b61de0da8c64d1db075b0c6a4860695
Autor:
Suzanne Maahs, Denise Leclair, Baltazar Gomez-Mancilla, Brian D. Kiluk, Velusamy Shanmuganathan Muthusamy, Partha S. Banerjee, Shyamashree Dasgupta, Katherine M. Waye
Publikováno v:
Frontiers in Psychiatry, Vol 15 (2024)
BackgroundCocaine use disorder (CUD) is characterized by the continued use of cocaine despite serious impacts on life. This study focused on understanding the perspective of individuals with current CUD, individuals in CUD remission, and their suppor
Externí odkaz:
https://doaj.org/article/43c4dba60c0d4275a249986db3e749b5
Autor:
Michel Laviolette, Suzanne Maahs, Veronica A. Swystun, Louis-Philippe Boulet, Irvin Mayers, Christopher Carlsten, Philip J. Lowe, Barbro Dahlén, Andrej Skerjanec, Miranda Bowen, Richard Leigh, Linda Hui, Beth E. Davis, Richard M. Watson, Gail M. Gauvreau, Kieran J. Killian, Joanne Milot, Anton Drollmann, Paul M. O'Byrne, J. Mark FitzGerald, Ann-Sofie Lantz, Karin Meiser, Nikolaos Lazarinis, Jonathan P. Arm, Donald W. Cockcroft
Publikováno v:
Journal of Allergy and Clinical Immunology. 138:1051-1059
Background Omalizumab is an established anti-IgE therapy for the treatment of allergic diseases that prevents IgE from binding to its receptor. QGE031 is an investigational anti-IgE antibody that binds IgE with higher affinity than omalizumab. Object
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0499d7d9d17d565f4598483e0cda9c9b
https://doi.org/10.1016/j.jaci.2016.02.027
https://doi.org/10.1016/j.jaci.2016.02.027
Autor:
Ramesh Sarangapani, Adele Noe, Gary Michael Ksander, William P. Dole, Weiyi Zheng, Dean F. Rigel, Jessie Gu, Monica Ligueros-Saylan, Suzanne Maahs, Priya Chandra, Arco Y. Jeng, Suliman Al-Fayoumi, Tsu-Han Lin
Publikováno v:
The Journal of Clinical Pharmacology. 50:401-414
Angiotensin receptor blockade and neprilysin (NEP) inhibition together offer potential benefits for the treatment of hypertension and heart failure. LCZ696 is a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b00bc62cfced09be93d79cfd80660b9a
https://doi.org/10.1177/0091270009343932
https://doi.org/10.1177/0091270009343932
Autor:
Axel Juan, Soniya Vaidya, Surendra Machineni, Günther Kaiser, Suzanne Maahs, Sanjeev Khindri, Hisanori Hara
Publikováno v:
Clinical pharmacology in drug development. 5(4)
This single-dose, 4-period crossover study evaluated the pharmacokinetics (PK) of the β2 -agonist indacaterol maleate and the corticosteroid mometasone furoate (MF) after inhalation of a fixed-dose combination (QMF149, indacaterol maleate/MF, 500/40
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e61fd062001d90b1760de48b9e50ddf7
https://pubmed.ncbi.nlm.nih.gov/27310329
https://pubmed.ncbi.nlm.nih.gov/27310329
Autor:
Conrad C. Bleul, David H. McKenna, Mary J. Laughlin, Darin Sumstad, Claudio G. Brunstein, Suzanne Maahs, John E. Wagner, Michael P. Cooke, Michael S. Perry, Anthony E. Boitano
Publikováno v:
Biology of Blood and Marrow Transplantation. 21(2):S48-S49
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::321149f9f45185fe261b746c6581afd9
Autor:
Anthony E. Boitano, John E. Wagner, Michael P. Cooke, Claudio G. Brunstein, Mary J. Laughlin, Michael S. Perry, Conrad C. Bleul, Suzanne Maahs, David H. McKenna, Darin Sumstad
Publikováno v:
Blood. 124:728-728
Background. The use of UCB has been substantially limited by the low finite number of CD34+ cells, resulting in prolonged periods of cytopenia and high risk of graft failure, restricting its widespread application particularly for adults. SR1 is an a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a7585f55ee42321778eb712837c3460
https://doi.org/10.1182/blood.v124.21.728.728
https://doi.org/10.1182/blood.v124.21.728.728
Autor:
Claudio G. Brunstein, Conrad C. Bleul, Suzanne Maahs, John E. Wagner, Michael P. Cooke, David H. McKenna, Darin Sumstad, Anthony E. Boitano
Publikováno v:
Blood. 122:698-698
Background Despite enhanced tolerability of HLA mismatch, the reduced number of HSPC in an UCB graft limits the use of this stem cell source because of delayed hematopoietic recovery and increased risk of graft failure, particularly in adults. For th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ce524fa600abb3fe6f71052db82fea3
https://doi.org/10.1182/blood.v122.21.698.698
https://doi.org/10.1182/blood.v122.21.698.698